Two-Drug cocktail shows promise against tough liver cancer
NCT ID NCT03211416
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs—sorafenib (a targeted therapy) and pembrolizumab (an immunotherapy)—in 37 people with advanced liver cancer that had spread. The goal was to see if the combo could shrink tumors and help people live longer. The trial was early-stage, so results are promising but not yet proven for widespread use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sorafenib and pembrolizumab (a targeted therapy and an immunotherapy drug combination)
What this could lead to
If it works, this combination could offer a new treatment option for advanced liver cancer, potentially shrinking tumors and extending survival.
What could go wrong
This was a small, early-phase trial (37 people), so results may not apply to everyone. Side effects from the drug combination can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ADULT HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Robert H Lurie Comprehensive Cancer Center
Chicago, Illinois, 60611, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States